Emergent BioSolutions | EBS - Zysk Brutto Na Sprzedaży





Zysk Brutto Na Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
ALKERMES USD 331.33M 7M 2026-03
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
Amarin USD 23.17M 961K 2025-12
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Coherus Biosciences USD 8.7M 853K 2025-12
Exelixis USD 590.86M 18.68M 2026-03
Glaxosmithkline GBP 5.75B 2.99B 2026-03
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 243M 48M 2026-03
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
Lonza CHF 1.29B 248M 2025-06
Merck USD 10.85B 2.57B 2025-12
Moderna USD -566M 792M 2026-03
Myriad Genetics USD 146.8M 3M 2025-12
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 800.7M 12.8M 2026-03
Pacira USD 126.64M 15.61M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Xoma 992K 846K 2024-06